Potential conflict of interest: The following authors are employees of Gilead Sciences and hold stock interest in the company: Leland Yee, Phillip Dinh, John Flaherty, Kathryn Kitrinos, and Eduardo B. Martins. Jan Sperl and Zahary Krastev have received grants from Gilead. Patrick Marcellin advises, is on the speakers' bureau of, and received grants from Roche, Gilead, Janssen, and MSD. He advises and is on the speakers' bureau of Bristol-Myers Squibb, Novartis, Vertex, Boehringer Ingleheim, Abbott, and Pfizer. Stuart Gordon has received research/grant support from Abbott Laboratories, Bristol-Myers Squibb, Exalenz Bioscience, Gilead Sciences, GlaxoSmithKline, Intercept Pharmaceuticals, Merck & Co., Roche, and Vertex Pharmaceuticals; been a consultant for Achillon Pharmaceuticals, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences, Merck & Co.; served on data monitoring boards for Janssen Pharmaceuticals.
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
Version of Record online: 3 MAY 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 58, Issue 2, pages 505–513, August 2013
How to Cite
Gordon, S. C., Krastev, Z., Horban, A., Petersen, J., Sperl, J., Dinh, P., Martins, E. B., Yee, L. J., Flaherty, J. F., Kitrinos, K. M., Rustgi, V. K. and Marcellin, P. (2013), Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology, 58: 505–513. doi: 10.1002/hep.26277
Funding for this study was provided by Gilead Sciences, Inc. (Foster City, CA).
See Editorial on Page 483
- Issue online: 29 JUL 2013
- Version of Record online: 3 MAY 2013
- Accepted manuscript online: 30 JAN 2013 12:47PM EST
- Manuscript Accepted: 28 DEC 2012
- Manuscript Received: 27 AUG 2012
Additional Supporting Information may be found in the online version of this article.
|hep26277-sup-0001-suppfig1.tif||1468K||Supplementary Figure 1. DNA profile of 29 patients with high viral load who added FTC during the first 240 weeks of the study. One subject added FTC at the discretion of the investigator, but was not eligible for FTC per study criteria.|
|hep26277-sup-0002-supptables.doc||61K||Supplementary Tables 1 and 2|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.